Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Longbio Pharma logo — A biotech to R&D innovative antibody/protein drugs of allerg...

Longbio Pharma

A biotech to R&D innovative antibody/protein drugs of allergic and complement diseases.

Founded 2020 2 employees Series B Total: $100.00M Biotechnology, Pharmaceutical

General Information

Company Name Longbio Pharma
Founded Year 2020
Employees 2
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Longbio Pharma. To contact Longbio Pharma, visit longbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Longbio Pharma compare?

A PDF of Longbio Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Longbio Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Longbio Pharma

Longbio Pharma is a biotech startup founded in 2018, based in Zhangjiang Hi-tech Park, Shanghai. With a team of 40+ scientists boasting over 10 years of experience in developing protein drugs, including antibodies and fusion proteins, Longbio Pharma has already achieved significant success. The co-founder team has a track record of successfully bringing two drugs to market, with accumulated global sales reaching USD 30 billion. Currently, the company is focused on R&D for innovative drugs targeting autoimmune and rare diseases, specifically in the areas of allergy and complement. In October 2023, Longbio Pharma secured a Series B investment of CNY 100.00 million from a consortium of investors including Oriental Fortune Capital, Shanxi Securities Investment, Huzhou Youcheng, Hefei Hongda, and Changshu Wuyue Angel Venture Capital. This recent injection of funding reflects growing confidence in the potential of Longbio Pharma's innovative approach to treating challenging medical conditions, positioning the company for further breakthroughs in the biotechnology and pharmaceutical industries.

Business keywords: Biotech, R&D, Antibody drugs, Protein drugs, Allergic diseases, Complement diseases, Drug development, Autoimmune diseases, Rare diseases, Shanghai, Zhangjiang Hi-tech Park, Scientist team, Co-founder team, Innovation, Pharma

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY100.00M 5
Oriental Fortune Capital Shanxi Securities Investment
Oriental Fortune Capital, Shanxi Securities Investment +3
31 Oct 2023

Longbio Pharma Alternatives & Competitors

View All Alternatives
Longbio Pharma vs
Henlius
Henlius China

Reliable Quality · Affordable Innovation

Venture round
492 employees
Biotechnology, Health Care
Longbio Pharma vs
Immunophage Biotech
Immunophage Biotech

Pioneering immune-regulating medicines to combat cancer, autoimmune diseases, and neurodegenerative...

1 employees
Biotechnology, Pharmaceutical
Longbio Pharma vs
Intercept Pharmaceuticals
Intercept Pharmaceuticals United States

Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.

Post-IPO Debt
376 employees
Biotechnology, Health Care
View all alternatives

FAQ About Longbio Pharma

A biotech to R&D innovative antibody/protein drugs of allergic and complement diseases.
Longbio Pharma was founded in 2020.
Longbio Pharma operates in Biotechnology and Pharmaceutical. Its work centres on Biotech, R&D, Antibody drugs and Protein drugs.
Longbio Pharma has approximately 2 employees.
Longbio Pharma has completed 1 funding round, raising a total of $100.00M. The latest funding stage is Series B.
Top alternatives and competitors to Longbio Pharma include Henlius, Immunophage Biotech, Intercept Pharmaceuticals, Calypso Biotech, Polymed Biopharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Longbio Pharma and Henlius are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Longbio Pharma, https://bouncewatch.com/company/longbio-pharma, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout